IGI Logo

Zydus Lifesciences is currently trading at Rs. 584.20, up by 2.15 points or 0.37% from its previous closing of Rs. 582.05 on the BSE.

The scrip opened at Rs. 586.05 and has touched a high and low of Rs. 587.45 and Rs. 581.30 respectively. So far 4495 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 588.85 on 28-Jun-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022.

Last one week high and low of the scrip stood at Rs. 588.85 and Rs. 548.10 respectively. The current market cap of the company is Rs. 58915.34 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg (USRLD: Ibrance Tablets, 75 mg, 100 mg, and 125 mg).

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells. The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad (India).

Palbociclib Tablets, 75 mg, 100 mg, and 125 mg had annual sales of $3.3 billion in the United States (IQVIA MAT April 2023). The group now has 373 approvals and has so far filed over 442 (as of March 31, 2023) ANDAs since the commencement of the filing process in FY 2003-04. 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company